home > drugs a-z list > visicol (sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous) drug center > visicol (sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous) drug - overdosage and contraindications

There have been no reported cases of overdosage with Visicol® (sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous) Tablets. Purposeful or accidental ingestion of more than the recommended dosage of Visicol® (sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous) Tablets might be expected to lead to severe electrolyte disturbances, including hyperphosphatemia, hypocalcemia, hypernatremia, or hypokalemia, as well as dehydration and hypovolemia, with attendant signs and symptoms of these disturbances. Certain severe electrolyte disturbances may lead to cardiac arrhythmias, seizure, renal failure, and death. The patient who has taken an overdosage should be monitored carefully, and treated symptomatically for complications until stable.

Visicol® (sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous) Tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy.

Visicol® (sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous) Tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.

Last reviewed on RxList: 4/17/2009
This monograph has been modified to include the generic and brand name in many instances.